Indacaterol maleate for the treatment of chronic obstructive pulmonary disease

Abstract

Importance of the field: Chronic obstructive pulmonary disease (COPD) is a partially reversible, progressive obstructive disorder. Bronchodilators are the mainstay of treatment since they improve lung function and patient-reported outcomes and reduce acute exacerbations. Long-acting inhaled bronchodilators (at present including the once-daily antimuscarinic tiotropium, and the twice-daily β₂-agonists formoterol and salmeterol) are recommended as first-line treatment for patients with persistent symptoms. Indacaterol maleate has been developed as a new once-daily inhaled β₂-selective agonist.

Areas covered in this review: This article reviews the published literature on the pharmacologic properties and the Phase II and III trials that have evaluated the safety and efficacy of this new agent.

What the reader will gain: The reader will obtain an appreciation of the safety and efficacy of indacaterol and the role that it might play in the future management of COPD of varying severity.

Take home message: Indacaterol is a new, once-daily β₂-agonist with an onset of action within 5 min and a duration of bronchodilation of at least 24 h. In doses of 150 and 300 μg, it has sustained benefits over 6 – 12 months with respect to both bronchodilation and patient-reported outcomes and is well-tolerated with an acceptable safety profile.

Keywords::

• COPD
• indacaterol
• long-acting antimuscarinic (LAMA)
• long-acting beta-agonist (LABA)
• tiotropium